We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$815M
AUM Growth
+$105M
Cap. Flow
+$27.8M
Cap. Flow %
3.41%
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
36
Reduced
33
Closed
18

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$22.9M
2
SDGR icon
Schrodinger
SDGR
+$16.6M
3
FTRE icon
Fortrea Holdings
FTRE
+$14.8M
4
OSCR icon
Oscar Health
OSCR
+$11.4M
5
HCA icon
HCA Healthcare
HCA
+$10.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
BSX icon
Boston Scientific
BSX
+$14.6M
3
KROS icon
Keros Therapeutics
KROS
+$10.8M
4
MTD icon
Mettler-Toledo International
MTD
+$9.1M
5
HUM icon
Humana
HUM
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Industrials 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
51
Arvinas
ARVN
$580M
$5.16M 0.63%
124,979
-42,022
-25% -$1.84M
MLTX icon
52
MoonLake Immunotherapeutics
MLTX
$1.47B
$5.08M 0.62%
101,071
+19,062
+23% +$1.03M
RCUS icon
53
Arcus Biosciences
RCUS
$3.69B
$4.91M 0.6%
259,920
+12,256
+5% +$212K
PHLT
54
DELISTED
Performant Healthcare Inc
PHLT
$4.88M 0.6%
1,659,100
+78,235
+5% +$224K
ITCI
55
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.84M 0.59%
69,892
-116,380
-62% -$8M
CRL icon
56
Charles River Laboratories
CRL
$13.6B
$4.8M 0.59%
+17,697
New +$4.23M
NAMS icon
57
NewAmsterdam Pharma
NAMS
$3.33B
$4.74M 0.58%
200,311
-100,439
-33% -$2.04M
CRNX icon
58
Crinetics Pharmaceuticals
CRNX
$8.96B
$4.73M 0.58%
101,119
-19,533
-16% -$764K
ATEC icon
59
Alphatec Holdings
ATEC
$1.49B
$4.64M 0.57%
+336,688
New +$4.99M
LAB icon
60
Standard BioTools
LAB
$312M
$4.53M 0.56%
1,670,401
+1,066,781
+177% +$2.58M
CNC icon
61
Centene
CNC
$33.1B
$4.38M 0.54%
+55,794
New +$4.31M
AUGX
62
DELISTED
Augmedix, Inc. Common Stock
AUGX
$4.36M 0.54%
1,066,109
+50,295
+5% +$225K
AKYA
63
DELISTED
Akoya BioSciences
AKYA
$4.3M 0.53%
917,442
+242,655
+36% +$1.26M
QTRX icon
64
Quanterix
QTRX
$139M
$4.15M 0.51%
176,112
+29,746
+20% +$737K
LYRA
65
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.99M 0.49%
12,845
-2,253
-15% -$600K
NRIX icon
66
Nurix Therapeutics
NRIX
$2.76B
$3.67M 0.45%
+250,000
New +$2.69M
MRUS
67
DELISTED
Merus
MRUS
$3.61M 0.44%
80,123
-77,694
-49% -$3.15M
NUVL
68
DELISTED
Nuvalent
NUVL
$3.59M 0.44%
47,808
-12,059
-20% -$960K
DVAX
69
DELISTED
Dynavax Technologies
DVAX
$3.31M 0.41%
266,510
+12,563
+5% +$164K
ELAN icon
70
Elanco Animal Health
ELAN
$11.1B
$3.28M 0.4%
+201,181
New +$3.15M
ESPR
71
DELISTED
Esperion Therapeutics
ESPR
$3.06M 0.38%
1,142,897
-282,307
-20% -$686K
CGEM icon
72
Cullinan Oncology
CGEM
$1.26B
$3.04M 0.37%
178,396
-351,481
-66% -$5.43M
IDYA icon
73
IDEAYA Biosciences
IDYA
$3.56B
$2.91M 0.36%
66,332
-63,933
-49% -$2.75M
URGN icon
74
UroGen Pharma
URGN
$2.39B
$2.76M 0.34%
184,184
+8,684
+5% +$142K
NKTX icon
75
Nkarta
NKTX
$171M
$2.72M 0.33%
+252,028
New +$2.62M
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Parkman Healthcare Partners held 117 positions worth $815M, up 15% from $710M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners deployed $27.8M of net new capital in Q1 2024, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was Eli Lilly: 32,117 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $14.6M trimmed.

  • Parkman Healthcare Partners's largest Q1 2024 buy was Eli Lilly: 32,117 shares worth $25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q1 2024, an estimated $16.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2024 reduction was Boston Scientific, cutting an estimated $14.6M.
  • Parkman Healthcare Partners fully exited Amgen in Q1 2024, selling an estimated $17.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $815M portfolio in Q1 2024.
  • Parkman Healthcare Partners opened 28 new positions and closed 18 in Q1 2024.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $815M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.